Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 10/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 4/20 | 0.54 |
| ▸ | CSF1R | P07333 | 2/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.51 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.51 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28325270 | 0.98 | MAP4K4 (0.74) | MAP4K4MAPTGRM1EGFRCSF1R | |
| SCHEMBL29817926 | 0.88 | MAP4K4 (0.61) | MAP4K4MAPTGRM1EGFRPI4KA | |
| SCHEMBL15587273 | 0.87 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL30658938 | 0.86 | MAP4K4 (0.62) | MAP4K4EGFRPI4KAPI4K2BPI4K2A | |
| SCHEMBL10975796 | 0.86 | MAP4K4 (0.62) | MAP4K4EGFRPI4KAPI4K2BPI4K2A | |
| Hydrochloric Acid SCHEMBL28185585 | 0.84 | MAP4K4 (0.60) | MAP4K4EGFRPI4KAPI4K2BPI4K2A | |
| SCHEMBL15587284 | 0.83 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL31060562 | 0.83 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL30513775 | 0.83 | MAP4K4 (0.72) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4386144 | 0.82 | MAP4K4 (0.58) | MAP4K4EGFRPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118255772-A | Quinazoline derivatives as antitumor agents | 苏州赞荣医药科技有限公司 | 2024-06-28 | — | — | CN | claimed |
| EP-4523755-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | F. Hoffmann-La Roche AG (CH) | 2025-03-19 | — | — | EP | disclosed |
| CN-118255772-A | Quinazoline derivatives as antitumor agents | 苏州赞荣医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-4360713-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | F. Hoffmann-La Roche AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20220411422-A1 | ERBB RECEPTOR INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-12-29 | — | — | US | disclosed |
| US-11447492-B2 | ERBB receptor inhibitors | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-09-20 | — | — | US | disclosed |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-04-26 | — | — | US | disclosed |
| US-20210085656-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-25 | — | — | US | disclosed |
| US-9796704-B2 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9359332-B2 | Processes for the preparation of substituted quinazolines | SYMPHONY EVOLUTION, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160129032-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| WO-2016053772-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-04-07 | — | — | WO | disclosed |
| US-9163006-B2 | — | — | 2015-10-20 | — | — | US | disclosed |
| US-20140155418-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8658654-B2 | Receptor-type kinase modulators and methods of use | SYMPHONY EVOLUTION, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-12-24 | — | — | US | disclosed |
| US-7576074-B2 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-08-18 | — | — | US | disclosed |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | MAP4K4 112/4885MAPT 3042/4885GRM1 1076/4885 |
| US-11447492-B2 | ERBB receptor inhibitors | ERBB2, EGFR, ERBB3 | MAP4K4 273/4885MAPT 2491/4885GRM1 632/4885 |
| US-20220411422-A1 | ERBB RECEPTOR INHIBITORS | ERBB2, EGFR, ERBB3 | MAP4K4 431/4885MAPT 1541/4885GRM1 867/4885 |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | ABL1, TP53, JAK1 | MAP4K4 72/4885MAPT 3619/4885GRM1 1110/4885 |
| US-20210085656-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, MAP4K5 | MAP4K4 9/4885MAPT 1952/4885GRM1 3258/4885 |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | MAP4K4 112/4885MAPT 3042/4885GRM1 1076/4885 |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ABL1, TP53, JAK1 | MAP4K4 72/4885MAPT 3619/4885GRM1 1110/4885 |
| US-20160129032-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | MAP4K4 112/4885MAPT 3042/4885GRM1 1076/4885 |
| US-20140155418-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | MAP4K4 112/4885MAPT 3042/4885GRM1 1076/4885 |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | MKNK1, MKNK2, MAP4K5 | MAP4K4 9/4885MAPT 1952/4885GRM1 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.